Literature DB >> 18176811

Low dose radiotherapy for adenotonsillar lymphoid hyperplasia in HIV-positive patients.

J Grobbelaar1, Riaz Y Seedat, A J Claassen, L Goedhals, M Nel.   

Abstract

Lymphoid hyperplasia is common in HIV positive patients. The aim of this study was to determine the response to radiotherapy. Thirty-three adult patients with recurrent tonsillitis or upper airway obstruction due to tonsillar hyperplasia and conformed histology of follicular hyperplasia were included. Thirteen underwent a 24 Gy course of radiotherapy and were followed up for a minimum of 16 weeks post-radiotherapy. There was a statistically significant decrease in the median tonsillar size (95% confidence interval [-3;-2]) and in the median CD4 count (95% CI [3;152]) after 16 weeks. None of the patients had acute tonsillitis or airway obstruction after radiotherapy. Low dose radiotherapy is effective in the management of adenotonsillar hyperplasia in HIV positive patients.

Entities:  

Mesh:

Year:  2008        PMID: 18176811     DOI: 10.1007/s00405-007-0573-9

Source DB:  PubMed          Journal:  Eur Arch Otorhinolaryngol        ISSN: 0937-4477            Impact factor:   2.503


  3 in total

1.  Radiation therapy as a treatment for benign lymphoepithelial parotid cysts in patients infected with human immunodeficiency virus-1.

Authors:  J Goldstein; J Rubin; C Silver; K Meritz; C Chao; J Ting; L Davis
Journal:  Int J Radiat Oncol Biol Phys       Date:  1992       Impact factor: 7.038

2.  Benign parotid hypertrophy on +HIV patients: limited late failures after external radiation.

Authors:  J J Beitler; R V Smith; A Brook; M Edelman; A Sharma; M Serrano; C E Silver; L W Davis
Journal:  Int J Radiat Oncol Biol Phys       Date:  1999-09-01       Impact factor: 7.038

3.  Low-dose radiotherapy for multicystic benign lymphoepithelial lesions of the parotid gland in HIV-positive patients: long-term results.

Authors:  J J Beitler; B Vikram; C E Silver; J S Rubin; J A Bello; R J Mitnick; G Gejerman; L W Davis
Journal:  Head Neck       Date:  1995 Jan-Feb       Impact factor: 3.147

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.